APOE基因型和他类药物对脂质结局的影响:元分析
Innocent G Asiimwe1, Tsegay Gebru2, Andrea L Jorgensen2
1Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
British journal of clinical pharmacology
|February 17, 2026
概括
APOE基因型影响了他类药物的反应. APOE ε2 载体表现出增强的低密度脂蛋白胆固醇降低,而 ε4 载体表现出减少的他类药物效应,突出了个性化医学的需要.
科学领域:
- 药物基因组学 药物基因组学
- 心血管遗传学 心血管遗传学
背景情况:
- 阿波利波蛋白E (APOE) 基因型是影响脂质代谢的已知因素.
- 类药物广泛用于预防心血管疾病,但个体反应各不相同.
- 了解APOE基因型在他类药物反应中的作用对于优化治疗至关重要.
研究的目的:
- 进行元分析以量化APOE基因型与他类药物治疗反应之间的关联.
- 更新现有证据,以了解不同APOE等位基因如何影响降脂结果.
主要方法:
- 进行了全面的元分析,搜索了七个主要的科学数据库.
- 选和数据提取涉及人类审查员和机器学习工具 (ASReview).
- 包括来自4352个非重复记录的52项研究,分析了对LDL-C,TC,TG和HDL-C的影响.
主要成果:
- 与E3载体相比,APOE ε2载体的LDL-C降低更大.
- 携带APOE ε4的携带者显示LDL-C,TC和TG的减少较小,HDL-C的增加较小.
- 异质性很高,部分由性别和家族性高胆固醇血症解释,在男性中观察到更强烈的基因型影响.
结论:
- APOE基因型显著影响着他类药物治疗反应.
- 个性化他类药物治疗方案应考虑个别的APOE基因型.
- 结合APOE等遗传因素可以导致更有效的脂质管理.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Atherosclerosis III: Management
460
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460
Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20
Atherosclerosis I: Introduction
1.4K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.4K
Cholesterol: Significance and Regulation
1.5K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
24
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24


